PROCEPT BioRobotics (PRCT) Operating Income (2020 - 2026)

PROCEPT BioRobotics (PRCT) has 7 years of Operating Income data on file, last reported at -$32.6 million in Q1 2026.

• Quarterly Operating Income fell 18.84% year-over-year to -$32.6 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$109.0 million (down 13.1% YoY) and the FY2025 annual result came in at -$103.9 million, down 7.5% from the prior year.
• Operating Income fell to -$32.6 million in Q1 2026 per PRCT's latest filing, from -$31.0 million in the prior quarter.
• Across five years, Operating Income topped out at -$15.7 million in Q1 2022 and bottomed at -$32.6 million in Q1 2026.
• The 5-year median for Operating Income is -$25.6 million (2023), against an average of -$24.9 million.
• The widest annual swing landed in 2023, when Operating Income sank 80.7%; it then soared 33.32% in 2024.
• Tracing PRCT's Operating Income over 5 years: stood at -$25.0 million in 2022, then declined by 18.04% to -$29.6 million in 2023, then soared by 33.32% to -$19.7 million in 2024, then slumped by 57.49% to -$31.0 million in 2025, then declined by 5.04% to -$32.6 million in 2026.
• Per Business Quant, the three latest PRCT Operating Income figures stand at -$32.6 million (Q1 2026), -$31.0 million (Q4 2025), and -$23.2 million (Q3 2025).

Peer Comparison